Movement by states to set up prescription drug affordability boards (PDABs) is growing in 2024, but the boards’ ultimate success in lowering drug prices hinges on details written into state bills, including how a board would evaluate affordability, and whether drug makers are able to successfully challenge the efforts in court. “I think we've seen broadening efforts within legislatures to either enact them or to update their existing statutes,” Manatt Health Partner Michael Kolber told Inside Health Policy . According...